- trans-o-flex increases revenue by 4.6 percent to €264 million compared to H1 2020
- Adjusted EBITDA increases by 4.0 percent to €31 million compared to H1 2020
- Volume of transported packages in Q2 2021 up by 6.2 percent Y-o-Y
Group revenues grew by 4.6 percent to €264 million in the first half of 2021 (H1 2020: €252 million) and adjusted EBITDA increased by 4.0 percent year-on-year to €31 million. In the same period, the Group’s business segment ThermoMed generated revenues of €39.7 (H1 2020: €36.3 million), a growth of 9.4 percent. The Group’s business segment trans-o-flex Express increased its revenues by 3.6 percent to €225 million (H1 2020: €217 million).
Wolfgang P. Albeck, CEO of trans-o-flex: “We are continuing on our growth path. The pandemic illustrates the importance of fast, secure and reliable logistics solutions for the pharmaceuticals. As the market leader for active temperature controlled transport of pharmaceutical products, and the expert for express specialized logistics, we are the partner of choice for our customers. The performance measures we have taken over recent years are now paying off. In the market for pharmaceuticals and express logistics for sensitive goods, we were able to show solid growth even in times of crisis, which makes us optimistic for the second half of the year.”
trans-o-flex benefits from several megatrends such as demographic change, which leads to a growing demand for pharmaceuticals or the growing shift to online-shopping which then drives demand for express solutions. At the same time, increasingly strict regulatory requirements for pharma logistics across the EU (Good Distribution Practice) drive higher quality standards for the entire distribution chain. This leads to a continuous increase in the demand for active temperature-controlled special logistics offered by trans-o-flex.
The safe distribution of COVID-19 test kits and vaccines has highlighted the importance of logistics solutions for highly sensitive pharmaceuticals – a market with high growth potential. The market for pharmaceutical and high-value sensitive logistics services in Germany and Austria was valued at €9.9 billion in 2020, and it is expected to grow to €12.2 billion in 2025, an increase by 23 percent.
With 50 years of experience and fully GDP-compliant networks for the active temperature-controlled transport of sensitive goods in the temperature ranges of 15-25 °C (trans-o-flex Express) and of 2-8 °C (ThermoMed Express) trans-o-flex is the expert for specialized express logistics in Germany and Austria. With its express network that specializes in offering consolidated transport of parcels and pallets and thus allows a broad portfolio of service combinations, combined with a commitment to service excellence and logistics innovations, trans-o-flex is leading the market for active temperature controlled transports of pharmaceuticals from manufacturers to wholesalers as well as deliveries to hospitals, pharmacies, doctor’s practices or nursing homes.
Information relating to financial terms
Adjusted EBITDA is measured as EBITDA excluding the effects of significant income and expense items which may have an impact on the comparability of earnings such as special non-recurring events.
DISCLAIMER
Forward-looking statements
This announcement contains "forward-looking statements". Forward-looking statements are sometimes, but not always, identified by their use of a date in the future or such words as "will", "could", "may", "should", "expects", "intends", "prepares" or "targets" (including in their negative form or other variations). By their nature, forward-looking statements are inherently predictive, speculative and involve risk and uncertainty because they relate to events and depend on circumstances that may or may not occur in the future. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. All subsequent written or oral forward-looking statements attributable to the Company, or any persons acting on their behalf are expressly qualified in their entirety by the factors referred to above. No assurances can be given that the forward-looking statements in this document will be realised. Any forward-looking statements are made of the date of this announcement. Subject to compliance with applicable law and regulations, trans-o-flex does not intend to update these forward-looking statements and does not undertake any obligation to do so.
Important Information
This announcement is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation of such jurisdiction or which would require any registration or licensing within such jurisdiction. Any failure to comply with these restrictions may constitute a violation of the laws of any such jurisdiction.
This announcement does not purport to contain all information required to evaluate the Company and/or its financial position. Financial information in this announcement is unaudited and certain financial information (including percentages) has been rounded according to established commercial standards. Certain data relating to market volumes included in this announcement is sourced from third party sources. Third party industry publications, studies and surveys generally state that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the fairness, quality, accuracy, relevance, completeness or sufficiency of such data. Such research and estimates, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness and are subject to change without notice. Accordingly, trans-o-flex expressly disclaims any responsibility for, or liability in respect of, such information and undue reliance should not be placed on such data.
